Cargando…
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of doxorubicin (DXR) and is one of the successful polymer micelle systems to exhibit an efficient accumulation in solid tumours in mice. The purpose of this study was to define the maximum-tolerated dose (MTD) and dose-li...
Autores principales: | Matsumura, Y, Hamaguchi, T, Ura, T, Muro, K, Yamada, Y, Shimada, Y, Shirao, K, Okusaka, T, Ueno, H, Ikeda, M, Watanabe, N |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410050/ https://www.ncbi.nlm.nih.gov/pubmed/15477860 http://dx.doi.org/10.1038/sj.bjc.6602204 |
Ejemplares similares
-
A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation
por: Hamaguchi, T, et al.
Publicado: (2007) -
Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil)
por: Tsukioka, Yoshihisa, et al.
Publicado: (2002) -
Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil
por: Yamada, Y, et al.
Publicado: (2003) -
Nanoalginates via Inverse-Micelle Synthesis: Doxorubicin-Encapsulation and Breast Cancer Cytotoxicity
por: Rosch, Justin G., et al.
Publicado: (2018) -
Physicochemical, Pharmacokinetic, and Toxicity Evaluation of Soluplus(®) Polymeric Micelles Encapsulating Fenbendazole
por: Jin, Ik Sup, et al.
Publicado: (2020)